SHL Telemedicine (NASDAQ:SHLT) versus SBC Medical Group (NASDAQ:SBC) Financial Contrast

SBC Medical Group (NASDAQ:SBC) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Analyst Recommendations

This is a summary of current ratings and target prices for SBC Medical Group and SHL Telemedicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	0	0	0	0	0.00
SHL Telemedicine	0	0	1	0	3.00

SHL Telemedicine has a consensus target price of $11.00, suggesting a potential upside of 264.24%. Given SHL Telemedicine’s stronger consensus rating and higher probable upside, analysts clearly believe SHL Telemedicine is more favorable than SBC Medical Group.

Earnings and Valuation

This table compares SBC Medical Group and SHL Telemedicine”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$223.34 million	3.03	$340,000.00	N/A	N/A
SHL Telemedicine	$55.94 million	0.79	-$7.06 million	N/A	N/A

SBC Medical Group has higher revenue and earnings than SHL Telemedicine.

Profitability

This table compares SBC Medical Group and SHL Telemedicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	N/A	-11.59%	-7.05%
SHL Telemedicine	N/A	N/A	N/A

Insider & Institutional Ownership

60.8% of SBC Medical Group shares are owned by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are owned by institutional investors. 63.9% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

SBC Medical Group has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, SHL Telemedicine has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500.

Summary

SBC Medical Group beats SHL Telemedicine on 6 of the 11 factors compared between the two stocks.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.

About SHL Telemedicine

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.